Outcome

The study has provided compelling evidence that hyperbaric oxygen (HBO) therapy can effectively suppress HIV-1 replication. Administering HBO at 2.4 ATA with 100% oxygen over five sessions resulted in significant increases in NFκB and interferon α2 mRNA expression and p21 protein levels. Additionally there was a notable reduction in HIV-1 p24 antigen levels indicating that HBO exposure successfully inhibited HIV replication in infected cells.

Introduction

Hyperbaric oxygen (HBO) therapy has emerged as a promising complementary treatment for various medical conditions including infections and inflammatory diseases. This study specifically investigates the potential of HBO therapy to suppress HIV replication. Utilizing an in vitro model with peripheral blood mononuclear cells (PBMCs) from healthy volunteers researchers exposed these cells to hyperbaric oxygen at 2.4 ATA (atmospheres absolute) to determine its impact on key cellular factors involved in HIV-1 replication.

The findings demonstrated a significant increase in the expression of transcription factor NFκB and interferon α2 mRNA in the HBO-treated group compared to the control group. Concurrently the levels of HIV-1 p24 antigen a marker of HIV replication were notably lower in the HBO group. Additionally the study observed enhanced expression of the p21 protein a cellular inhibitor of viral replication. These results collectively suggest that HBO therapy can enhance cellular adaptive responses and inhibit HIV replication pointing to its potential as an adjunctive treatment strategy for managing HIV infection.

Results

The study demonstrated that hyperbaric oxygen therapy (HBO) at 2.4 ATA effectively suppressed HIV replication in infected peripheral blood mononuclear cells (PBMCs). HBO treatment significantly increased the expression of key cellular transcription factors and mRNA associated with antiviral responses. Specifically the expression of NFκB increased from 0.20% in the control group to 0.43% in the HBO-treated group. Similarly interferon α2 mRNA expression was significantly upregulated with a 22.54-fold increase in the HBO group compared to a -21.11-fold change in the control group. The study also noted an elevation in p21 protein levels which were higher in the HBO group (0.25%) compared to 0% in the control group.

Importantly the treatment led to a significant reduction in HIV-1 p24 antigen levels from 264.8 ng/ml in the control group to 233.8 ng/ml in the HBO-treated group indicating suppressed HIV replication. These changes were observed without significant alterations in interferon α protein levels between the two groups.

The therapeutic effects of HBO were attributed to the enhanced production of reactive oxygen species (ROS) and reactive nitrogen species (RNS) during exposure which facilitated adaptive cellular responses to inhibit HIV-1 replication. Overall the results suggest that HBO therapy may augment the body’s natural antiviral defense mechanisms and serve as a complementary treatment for HIV infection effectively reducing viral replication in infected cells.

Conclusion

In conclusion this study provides compelling evidence that hyperbaric oxygen (HBO) therapy at 2.4 ATA significantly suppresses HIV-1 replication in infected peripheral blood mononuclear cells (PBMCs). The treatment notably increased the expression of NFκB and interferon α2 mRNA along with higher levels of p21 protein while reducing HIV-1 p24 antigen levels indicating a marked inhibition of viral replication. These results suggest that HBO-induced cellular responses mediated by reactive oxygen and nitrogen species play a pivotal role in this antiviral effect. The findings underscore the potential of HBO therapy as a complementary treatment for HIV infection offering new avenues for enhancing the body’s natural defense mechanisms against the virus. Further research is warranted to explore the broader clinical applications optimize treatment protocols and understand the long-term effects of HBO therapy in managing HIV infection.